ENDPOINTS

'Optimizing R&D structure is also on the horizon, without exception,' new Sumitomo Pharma CEO says

10 months ago

Pharma

Nikkei Biotechnology

Yuhan, Ubix ink licensing deal; Xenpozyme's royalty deal

10 months ago

News Briefing

Tracon to seek ‘strategic’ options; Ovid to lay off 17 workers

10 months ago

News Briefing

Savara’s $100M offering; New biotech to test Eisai drug in Ph2

11 months ago

News Briefing

Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience

11 months ago

News Briefing

Taysha’s $75M offering; Augustine raises €17M

11 months ago

News Briefing

Zealand Pharma aims to raise $900M; Boehringer discontinues three Phase 2 trials

11 months ago

News Briefing

Biopharma leaders charting a path for the industry's LGBTQ+ community

11 months ago

People

Special

Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down

11 months ago

News Briefing

Forbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure

11 months ago

News Briefing

A new obesity biotech; UroGen aims to raise $107M

11 months ago

News Briefing

Argenx drops post-Covid syndrome program; Mirum picks a dose for bile duct disease drug

11 months ago

News Briefing

Takeda signs option deal for TKI inhibitor; Enveda's $55M raise

11 months ago

News Briefing

Alzheon raises $100M; Regeneron ends mid-stage trial

11 months ago

News Briefing

ADC startup raises €30M; Cyrus Biotechnology to spin out Levitate Bio

11 months ago

News Briefing

Shionogi inks deal for preclinical hearing loss therapies; Alvotech’s refinancing pact

11 months ago

News Briefing

ArriVent inks ADC deal with Alphamab; Annexon's $125M offering

11 months ago

News Briefing

Corrected: Vilya raises $21M in Series A extension; Shionogi to open research center in San Diego

11 months ago

News Briefing

Novartis shares updated data for BTK inhibitor; Astellas resubmits BLA for cancer drug after CRL

11 months ago

News Briefing

Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering

12 months ago

News Briefing

Insmed, Merus announce public offerings; AI startup raises $13M seed round

12 months ago

News Briefing

Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement

12 months ago

News Briefing

#ASCO24: A roundup of the latest data from Merus, MorphoSys and others

Last year

R&D

ASCO abstracts are out, with data for ADCs, Nimbus' next-gen I/O drug and more

Last year

R&D

Pharma

about the author

author articles

'Optimizing R&D structure is also on the horizon, without exception,' new Sumitomo Pharma CEO says

Yuhan, Ubix ink licensing deal; Xenpozyme's royalty deal

Tracon to seek ‘strategic’ options; Ovid to lay off 17 workers

Savara’s $100M offering; New biotech to test Eisai drug in Ph2

Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience

Taysha’s $75M offering; Augustine raises €17M

Zealand Pharma aims to raise $900M; Boehringer discontinues three Phase 2 trials

Biopharma leaders charting a path for the industry's LGBTQ+ community

Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down

Forbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure

A new obesity biotech; UroGen aims to raise $107M

Argenx drops post-Covid syndrome program; Mirum picks a dose for bile duct disease drug

Takeda signs option deal for TKI inhibitor; Enveda's $55M raise

Alzheon raises $100M; Regeneron ends mid-stage trial

ADC startup raises €30M; Cyrus Biotechnology to spin out Levitate Bio

Shionogi inks deal for preclinical hearing loss therapies; Alvotech’s refinancing pact

ArriVent inks ADC deal with Alphamab; Annexon's $125M offering

Corrected: Vilya raises $21M in Series A extension; Shionogi to open research center in San Diego

Novartis shares updated data for BTK inhibitor; Astellas resubmits BLA for cancer drug after CRL

Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering

Insmed, Merus announce public offerings; AI startup raises $13M seed round

Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement

#ASCO24: A roundup of the latest data from Merus, MorphoSys and others

ASCO abstracts are out, with data for ADCs, Nimbus' next-gen I/O drug and more